Parvovirus-B19-associated complications in renal transplant recipients

SUMMARY: Parvovirus B19 is a common human pathogen, causing erythema infectiosum in children, hydrops fetalis in pregnant women, and transient aplastic crisis in patients with chronic hemolytic anemia. Immunosuppressed patients can fail to mount an effective immune response to B19, resulting in prolonged or persistent viremia. Renal transplant recipients can develop symptomatic B19 infections as a result of primary infection acquired via the usual respiratory route or via the transplanted organ, or because of reactivation of latent or persistent viral infection. The most common manifestations of B19 infection in immunosuppressed patients are pure red cell aplasia and other cytopenias. Thus, this diagnosis should be considered in transplant recipients with unexplained anemia and reticulocytopenia or pancytopenia. Collapsing glomerulopathy and thrombotic microangiopathy have been reported in association with B19 infection in renal transplant recipients, but a causal relationship has not been definitively established. Prompt diagnosis of B19 infection in the renal transplant recipient requires a high index of suspicion and careful selection of diagnostic tests, which include serologies and polymerase chain reaction. Most patients benefit from intravenous immunoglobulin therapy and/or alteration or reduction of immunosuppressive therapy. Conservative therapy might be sufficient in some cases. Copyright (C) 2007 Nature Publishing Group; References: 1 Young NS and Brown KE (2004) Parvovirus B19. N Engl J Med 350: 586-597 2 Heegaard ED and Brown KE (2002) Human parvovirus B19. Clin Microbiol Rev 15: 485-505 3 Kelly HA et al. (2000) The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect 124: 449-457 4 Cohen BJ and Buckley MM (1988) The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 25: 151-153 5 Nguyen QT et al. (2002) Identification and characterization of a second novel human erythrovirus variant, A6. Virology 301: 374-380 6 Servant A et al. (2002) Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 76: 9124-9134 7 Ekman A et al. (2007) Biological and immunological relations among human parvovirus B19 genotypes 1-3. J Virol 81: 6927-6935 8 Brown KE (2004) Variants of B19. Dev Biol (Basel) 118: 71-77 9 Hokynar K et al. (2002) A new parvovirus genotype persistent in human skin. Virology 302: 224-228 10 Ozawa K and Young N (1987) Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol 61: 2627-2630 11 Momoeda M et al. (1994) A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol 68: 8443-8446 12 Rosenfeld SJ et al. (1992) Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 89: 2023-2029 13 Brown KE et al. (1993) Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262: 114-117 14 Cooling LL et al. (1995) Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 172: 1198-1205 15 Weigel-Kelley KA et al. (2003) [alpha]5[beta]1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of [beta]1 integrin for viral entry. Blood 102: 3927-3933 16 Munakata Y et al. (2005) Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106: 3449-3456 17 Moffatt S et al. (1998) Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 72: 3018-3028 18 Zhi N et al. (2006) Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J Virol 80: 5941-5950 19 Anderson MJ et al. (1985) Experimental parvoviral infection in humans. J Infect Dis 152: 257-265 20 Takahashi T et al. (1990) Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 75: 603-610 21 Morita E et al. (2003) Human parvovirus B19 nonstructural protein (NS1) induces cell cycle arrest at G1 phase. J Virol 77: 2915-2921 22 Serjeant GR et al. (1993) Human parvovirus infection in homozygous sickle cell disease. Lancet 341: 1237-1240 23 Saarinen UM et al. (1986) Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 67: 1411-1417 24 Modrow S and Dorsch S (2002) Antibody responses in parvovirus B19 infected patients. Pathol Biol (Paris) 50: 326-331 25 Corcoran A and Doyle S (2004) Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 53: 459-475 26 Corcoran A et al. (2006) Establishment of functional B cell memory against parvovirus B19 capsid proteins may be associated with resolution of persistent infection. J Med Virol 78: 125-128 27 Isa A et al. (2006) Aberrant cellular immune responses in humans infected persistently with parvovirus B19. J Med Virol 78: 129-133 28 Tolfvenstam T et al. (2001) Direct ex vivo measurement of CD8+ T-lymphocyte responses to human parvovirus B19. J Virol 75: 540-543 29 Isa A et al. (2005) Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med 2: e343 30 Kasprowicz V et al. (2006) Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19. J Virol 80: 11209-11217 31 Norbeck O et al. (2005) Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 79: 12117-12121 32 Yaegashi N et al. (1989) Enzyme-linked immunosorbent assay for IgG and IgM antibodies against human parvovirus B19: use of monoclonal antibodies and viral antigen propagated in vitro. J Virol Methods 26: 171-181 33 Palmer P et al. (1996) Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins. Clin Diagn Lab Immunol 3: 236-238 34 Zuffi E et al. (2001) Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 14: 151-158 35 Takahashi M et al. (1995) Human parvovirus B19 infection: immunohistochemical and electron microscopic studies of skin lesions. J Cutan Pathol 22: 168-172 36 Magro CM et al. (2000) The cutaneous manifestations of human parvovirus B19 infection. Hum Pathol 31: 488-497 37 Dijkmans BA et al. (1988) Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum 31: 279-281 38 Kerr JR et al. (2004) Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J Med Virol 74: 147-155 39 Kurtzman G et al. (1989) Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 321: 519-523 40 Neild G et al. (1986) Parvovirus infection after renal transplant. Lancet 2: 1226-1227 41 Eid AJ et al. (2006) Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 43: 40-48 42 Zolnourian ZR et al. (2000) Parvovirus B19 in kidney transplant patients. Transplantation 69: 2198-2202 43 Ki CS et al. (2005) Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant 19: 751-755 44 Bertoni E et al. (1997) Aplastic anemia due to B19 parvovirus infection in cadaveric renal transplant recipients: an underestimated infectious disease in the immunocompromised host. J Nephrol 10: 152-156 45 Yango A Jr et al. (2002) Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis 4: 163-166 46 Murer L et al. (2000) Thrombotic microangiopathy associated with parvovirus B19 infection after renal transplantation. J Am Soc Nephrol 11: 1132-1137 47 Bertoni E et al. (1995) Severe aplastic anaemia due to B19 parvovirus infection in renal transplant recipient. Nephrol Dial Transplant 10: 1462-1463 48 Sturm I et al. (1996) Chronic parvovirus B19 infection-associated pure red cell anaemia in a kidney transplant recipient. Nephrol Dial Transplant 11: 1367-1370 49 Uemura N et al. (1995) Pure red cell aplasia caused by parvovirus B19 infection in a renal transplant recipient. Eur J Haematol 54: 68-69 50 Cavallo R et al. (2003) B19 virus infection in renal transplant recipients. J Clin Virol 26: 361-368 51 Bertoni E et al. (1997) Unusual incidence of aplastic anaemia due to B-19 parvovirus infection in renal transplant recipients. Transplant Proc 29: 818-819 52 Egbuna O et al. (2006) A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant 6: 225-231 53 Renoult E et al. (2006) Recurrent anemia in kidney transplant recipients with parvovirus B19 infection. Transplant Proc 38: 2321-2323 54 Crook TW et al. (2000) Unusual bone marrow manifestations of parvovirus B19 infection in immunocompromised patients. Hum Pathol 31: 161-168 55 Onguru P et al. (2006) Glomerulonephritis associating parvovirus B19 infection. Ren Fail 28: 85-88 56 Ieiri N et al. (2005) Characteristics of acute glomerulonephritis associated with human parvovirus B19 infection. Clin Nephrol 64: 249-257 57 Iwafuchi Y et al. (2002) Acute endocapillary proliferative glomerulonephritis associated with human parvovirus B19 infection. Clin Nephrol 57: 246-250 58 Ohtomo Y et al. (2003) Nephrotic syndrome associated with human parvovirus B19 infection. Pediatr Nephrol 18: 280-282 59 Komatsuda A et al. (2000) Endocapillary proliferative glomerulonephritis in a patient with parvovirus B19 infection. Am J Kidney Dis 36: 851-854 60 Mori Y et al. (2002) Association of parvovirus B19 infection with acute glomerulonephritis in healthy adults: case report and review of the literature. Clin Nephrol 57: 69-73 61 Takeda S et al. (2001) Renal involvement induced by human parvovirus B19 infection. Nephron 89: 280-285 62 Taylor G et al. (2001) Renal involvement of human parvovirus B19 in an immunocompetent host. Clin Infect Dis 32: 167-169 63 Wierenga KJ et al. (1995) Glomerulonephritis after human parvovirus infection in homozygous sickle-cell disease. Lancet 346: 475-476 64 Tolaymat A et al. (1999) Parvovirus glomerulonephritis in a patient with sickle cell disease. Pediatr Nephrol 13: 340-342 65 Moudgil A et al. (2001) Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 59: 2126-2133 66 Barsoum NR et al. (2002) Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant 2: 425-428 67 Swaminathan S et al. (2006) Collapsing and noncollapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 21: 2607-2614 68 Keung YK et al. (1999) Concomitant parvovirus B19 and cytomegalovirus infections after living-related renal transplantation. Nephrol Dial Transplant 14: 469-471 69 Becker MR et al. (2005) Renal anemia aggravated by long-term parvovirus B19 and cytomegalovirus infection in a renal transplant patient: case report and evaluation of B19 seroprevalence in dialysis patients. Transplant Proc 37: 4306-4308 70 Marchand S et al. (1999) Human parvovirus B19 infection in organ transplant recipients. Clin Transplant 13: 17-24 71 Al-Khaldi N et al. (1994) Dual infection with human herpesvirus type 6 and parvovirus B19 in a renal transplant recipient. Pediatr Nephrol 8: 349-350 72 Peterlana D et al. (2006) Serologic and molecular detection of human Parvovirus B19 infection. Clin Chim Acta 372: 14-23 73 Musiani M et al. (1995) Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 172: 1360-1363 74 Soderlund-Venermo M et al. (2002) Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 50: 307-316 75 Hokynar K et al. (2004) Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J Clin Microbiol 42: 2013-2019 76 Liefeldt L et al. (2005) Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J Med Virol 75: 161-169 77 Liefeldt L et al. (2002) Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy. Nephrol Dial Transplant 17: 1840-1842 78 Geetha D et al. (2000) Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 14: 586-591 79 Subtirelu MM et al. (2005) Acute renal failure in a pediatric kidney allograft recipient treated with intravenous immunoglobulin for parvovirus B19 induced pure red cell aplasia. Pediatr Transplant 9: 801-804 80 Tsinalis D et al. (2002) Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. Am J Kidney Dis 40: 667-670 81 Levy JB and Pusey CD (2000) Nephrotoxicity of intravenous immunoglobulin. QJM 93: 751-755 82 Shimmura H et al. (2000) Discontinuation of immunosuppressive antimetabolite for parvovirus B19-associated anemia in kidney transplant patients. Transplant Proc 32: 1967-1970 83 Wong TY et al. (1999) Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis 34: 1132-1136 84 Choi SH et al. (2002) A case of persistent anemia in a renal transplant recipient: association with parvovirus B19 infection. Scand J Infect Dis 34: 71-75 85 Gregoor PS and Weimar W (2005) Tacrolimus and pure red-cell aplasia. Am J Transplant 5: 195-196 86 Arzouk N et al. (2006) Parvovirus B19-induced anemia in renal transplantation: a role for rHuEPO in resistance to classical treatment. Transpl Int 19: 166-169 87 Wicki J et al. (1997) Parvovirus [correction of Parovirus] B19-induced red cell aplasia in solid-organ transplant recipients: two case reports and review of the literature. Hematol Cell Ther 39: 199-204 88 Kerr JR et al. (2003) Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J Clin Pathol 56: 725-727 89 Moore TL (2000) Parvovirus-associated arthritis. Curr Opin Rheumatol 12: 289-294 90 Kerr JR (2000) Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 59: 672-683 91 Lu J et al. (2006) Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 193: 582-590 92 Ergaz Z and Ornoy A (2006) Parvovirus B19 in pregnancy. Reprod Toxicol 21: 421-435 93 Yaegashi N et al. (1999) Serologic study of human parvovirus B19 infection in pregnancy in Japan. J Infect 38: 30-35 94 Enders M et al. (2004) Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 24: 513-518 95 Lee PC et al. (2000) Parvovirus B19-related acute hepatitis in an immunosuppressed kidney transplant. Nephrol Dial Transplant 15: 1486-1488 96 Shan YS et al. (2001) Fibrosing cholestatic hepatitis possibly related to persistent parvovirus B19 infection in a renal transplant recipient. Nephrol Dial Transplant 16: 2420-2422 97 Laurenz M et al. (2006) Severe parvovirus B19 encephalitis after renal transplantation. Pediatr Transplant 10: 978-981 98 Bilge I et al. (2005) Central nervous system vasculitis secondary to parvovirus B19 infection in a pediatric renal transplant patient. Pediatr Nephrol 20: 529-533 99 Moudgil A et al. (1997) Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 64: 1847-1850